Aegis reaffirmed their buy rating on shares of DarioHealth (NASDAQ:DRIO) in a report published on Friday morning.

DarioHealth (NASDAQ DRIO) traded down $0.06 on Friday, reaching $1.43. 20,800 shares of the company traded hands, compared to its average volume of 76,657. DarioHealth has a 1-year low of $1.33 and a 1-year high of $4.70.

COPYRIGHT VIOLATION WARNING: “DarioHealth (DRIO) Earns Buy Rating from Aegis” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at

DarioHealth Company Profile

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

Receive News & Ratings for DarioHealth Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp and related companies with's FREE daily email newsletter.